<参考にした文献> (1)イマチニブ投与後に腫瘍中心壊死巣が胃内腔と交通した胃原発巨大GISTの1例 栗田etal 徳島大外科 日臨外会誌70(4)1044-1048,2009 (注)母と酷似した例です。Imatinib 400 mg/dayで治療開始し,胃穿孔を起こした後,横隔膜の腫瘍は一部残存させ,胃と巨大GISTを摘出し,手術後Imatinib 400 mg/dayで寛解を得た例。 (2)The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors Margaret von Meheren Current Opinion in Oncology 2008, 20:428-432 (注)Imatinib術前,術後投与との見解。 (3)Surgery of residual disease following molecular-tageted therapy with imatinib mesylate in advanced/maetastatic GIST Alessandro Gronchi etal Annals of surgery2007, 245: 341-346 (注)Imatinib投与後の外科処置に否定的な見解。 (4) Personalized cancer therapy for gastrointestinal stromal tumor:synergizing tumor genotyping with imatinib plasma levels Andrea Marrari etal Current Opinion in Oncology 2010, 22:000-000 (注)Imatinibの有効性は血漿中濃度依存的で個体差が大きい。 (5) Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumor? Jean Yves Blay etal Current Opinion in Oncology 2009, 21:360-366 (注)Imatinibは耐性出現まで使用すべき。 (6)Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? single center experience Thomas Armbrust etal European Journal of Gastroenterology and Hepatology 2009, 21:819-823 (注)Imatinib耐性出現は約2年で50% (7)Gastrointestinal stromal tumors (Review and perspective) Bernadette Liegl-Atzwanger etal Virchows Arch 2010 456:111-127 (注)有用なreview。